# Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

> **NCT01763164** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 402 (actual)

## Conditions studied

- Metastatic or Unresectable Cutaneous Melanoma

## Interventions

- **DRUG:** MEK162
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01763164
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-12
- **Primary completion:** 2015-12-01
- **Final completion:** 2019-06-04
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2021-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763164, "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01763164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*